We are live on ! Find out more
SGTX

Sigilon Therapeutics, Inc. Common Stock

Delisted

SGTX was delisted on the 10th of August, 2023.

16 hedge funds and large institutions have $26.6M invested in Sigilon Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 9 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more capital invested

Capital invested by funds: $16.5M → $26.6M (+$10.1M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

50% less funds holding

Funds holding: 3216 (-16)

84% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 19

89% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 9

Holders
16
Holders Change
-16
Holders Change %
-50%
% of All Funds
0.25%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
3
Increased
1
Reduced
9
Closed
19
Calls
$293K
Puts
Net Calls
+$293K
Net Calls Change
+$267K
Name Holding Trade Value Shares
Change
Change in
Stake
VF
26
Virtu Financial
New York
-$26K -2,123 Closed
GSC
27
Ground Swell Capital
South Carolina
-$23.8K -1,972 Closed
SWM
28
Soundmark Wealth Management
Washington
-$23.8K -1,966 Closed
Northern Trust
29
Northern Trust
Illinois
-$22.4K -1,853 Closed
RJA
30
Raymond James & Associates
Florida
-$20.8K -1,723 Closed
Prudential Financial
31
Prudential Financial
New Jersey
-$9.86K -815 Closed
Barclays
32
Barclays
United Kingdom
-$2.18K -180 Closed
Federated Hermes
33
Federated Hermes
Pennsylvania
-$1.19K -98 Closed
UBS Group
34
UBS Group
Switzerland
-$658 -54 Closed
NECFA
35
New England Capital Financial Advisors
Connecticut
-$38 -3 Closed

SGTX Hedge Fund Activity: Q2 2023 in Review

16 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q2 2023, worth a combined $26.6M — up 61% from $16.5M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of SGTX and 3 opened new positions — a net loss of 16 holders — while 9 trimmed existing stakes and 1 added.

The largest buyer was Yakira Capital Management, opening a new position worth an estimated $288K. The largest seller was Cercano Management, exiting entirely with an estimated $823K sold.

  • 16 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q2 2023, down from 32 in Q1 2023.
  • Funds reported $26.6M of Sigilon Therapeutics, Inc. Common Stock stock for Q2 2023, up 61% quarter-over-quarter.
  • 3 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q2 2023 and 19 closed out, a net change of -16 holders.
  • The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q2 2023 was Yakira Capital Management, an estimated $288K added.
  • The largest Sigilon Therapeutics, Inc. Common Stock seller in Q2 2023 was Cercano Management, an estimated $823K sold.

Based on aggregated 13F filings for Q2 2023.